# Corvex, Inc.: financial statements, quarterly

MOVE · Nasdaq · CIK 1734750 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/move.md) · [Financials](/companies/move/financials.md) · [Filings](/companies/move/filings.md) · [Insiders](/companies/move/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/move/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.9](/filings/0001213900-25-091180.md) | [0.0](/filings/0001213900-24-068994.md) | [0.1](/filings/0001213900-25-110877.md) | [0.1 d](/filings/0001213900-26-036609.md) | [0.2](/filings/0001213900-26-058993.md) | [0.1](/filings/0001213900-26-090091.md) | [0.1](/filings/0001213900-25-110877.md) | [0.0 d](/filings/0001213900-26-036609.md) | [0.5](/filings/0001213900-26-058993.md) | [3.8](/filings/0001213900-26-090091.md) |
| Cost of revenue | $m | not reported | not reported | [1.2](/filings/0001213900-25-091180.md) | [0.4](/filings/0001213900-25-091181.md) | [0.8](/filings/0001213900-25-110877.md) | [0.6 d](/filings/0001213900-26-036609.md) | [0.6](/filings/0001213900-25-091180.md) | [0.4](/filings/0001213900-25-091181.md) | [0.3](/filings/0001213900-25-110877.md) | [1.0 d](/filings/0001213900-26-036609.md) | not reported | not reported |
| Research and development | $m | [5.6](/filings/0001213900-24-098474.md) | [3.2 d](/filings/0001213900-25-030345.md) | [2.9](/filings/0001213900-25-091180.md) | [2.9](/filings/0001213900-25-091181.md) | [3.4](/filings/0001213900-25-110877.md) | [2.0 d](/filings/0001213900-26-036609.md) | [2.4](/filings/0001213900-26-058993.md) | [1.4](/filings/0001213900-26-090091.md) | [1.2](/filings/0001213900-25-110877.md) | [0.8 d](/filings/0001213900-26-036609.md) | [0.8](/filings/0001213900-26-058993.md) | [1.4](/filings/0001213900-26-090091.md) |
| Selling, general and administrative | $m | [3.4](/filings/0001213900-24-098474.md) | not reported | not reported | not reported | [3.2](/filings/0001213900-24-098474.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(9.1)](/filings/0001213900-24-098474.md) | [(6.0) d](/filings/0001213900-25-030345.md) | [(5.8)](/filings/0001213900-25-091180.md) | [(6.4)](/filings/0001213900-25-091181.md) | [(7.4)](/filings/0001213900-25-110877.md) | [(4.7) d](/filings/0001213900-26-036609.md) | [(5.2)](/filings/0001213900-26-058993.md) | [(3.3)](/filings/0001213900-26-090091.md) | [(2.6)](/filings/0001213900-25-110877.md) | [(4.4) d](/filings/0001213900-26-036609.md) | [(4.8)](/filings/0001213900-26-058993.md) | [(15.2)](/filings/0001213900-26-090091.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001213900-25-110877.md) | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001213900-26-090091.md) |
| Net income | $m | [(9.0)](/filings/0001213900-24-098474.md) | [(6.0) d](/filings/0001213900-25-030345.md) | [(5.7)](/filings/0001213900-25-091180.md) | [(6.2)](/filings/0001213900-25-091181.md) | [(7.2)](/filings/0001213900-25-110877.md) | [(4.6) d](/filings/0001213900-26-036609.md) | [(5.2)](/filings/0001213900-26-058993.md) | [(3.2)](/filings/0001213900-26-090091.md) | [(4.0)](/filings/0001213900-25-110877.md) | [(5.9) d](/filings/0001213900-26-036609.md) | [(5.0)](/filings/0001213900-26-058993.md) | [(12.8)](/filings/0001213900-26-090091.md) |
| Diluted EPS | $ per share | [(2.65)](/filings/0001213900-24-098474.md) | not reported | [(1.53)](/filings/0001213900-25-091180.md) | [(0.93)](/filings/0001213900-25-091181.md) | [(10.56)](/filings/0001213900-25-110877.md) | not reported | [(5.35)](/filings/0001213900-26-058993.md) | [(3.05)](/filings/0001213900-26-090091.md) | [(4.73)](/filings/0001213900-25-110877.md) | not reported | [(3.13)](/filings/0001213900-26-058993.md) | [(5.12)](/filings/0001213900-26-090091.md) |
| Basic EPS | $ per share | [(2.65)](/filings/0001213900-24-098474.md) | not reported | [(1.53)](/filings/0001213900-25-091180.md) | [(0.93)](/filings/0001213900-25-091181.md) | [(10.56)](/filings/0001213900-25-110877.md) | not reported | [(5.35)](/filings/0001213900-26-058993.md) | [(3.05)](/filings/0001213900-26-090091.md) | [(4.73)](/filings/0001213900-25-110877.md) | not reported | [(3.13)](/filings/0001213900-26-058993.md) | [(5.12)](/filings/0001213900-26-090091.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.7](/filings/0001213900-23-086893.md) | [6.1](/filings/0001213900-25-030345.md) | [2.1](/filings/0001213900-24-044765.md) | [16.9](/filings/0001213900-24-068994.md) | [11.3](/filings/0001213900-24-098474.md) | [7.9](/filings/0001213900-26-036609.md) | [4.4](/filings/0001213900-25-091180.md) | [2.1](/filings/0001213900-25-091181.md) | [2.0](/filings/0001213900-25-110877.md) | [2.8](/filings/0001213900-26-090091.md) | [29.3](/filings/0001213900-26-058993.md) | [21.7](/filings/0001213900-26-090091.md) |
| Current assets | $m | [9.2](/filings/0001213900-23-086893.md) | [8.5](/filings/0001213900-25-030345.md) | [4.4](/filings/0001213900-24-044765.md) | [19.7](/filings/0001213900-24-068994.md) | [14.0](/filings/0001213900-24-098474.md) | [10.4](/filings/0001213900-26-036609.md) | [6.9](/filings/0001213900-25-091180.md) | [4.9](/filings/0001213900-25-091181.md) | [4.9](/filings/0001213900-25-110877.md) | [5.0](/filings/0001213900-26-090091.md) | [37.9](/filings/0001213900-26-058993.md) | [28.3](/filings/0001213900-26-090091.md) |
| Total assets | $m | [10.6](/filings/0001213900-23-086893.md) | [9.4](/filings/0001213900-25-030345.md) | [5.1](/filings/0001213900-24-044765.md) | [20.8](/filings/0001213900-24-068994.md) | [15.1](/filings/0001213900-24-098474.md) | [11.3](/filings/0001213900-26-036609.md) | [7.8](/filings/0001213900-25-091180.md) | [5.7](/filings/0001213900-25-091181.md) | [5.6](/filings/0001213900-25-110877.md) | [5.6](/filings/0001213900-26-090091.md) | [604](/filings/0001213900-26-058993.md) | [599](/filings/0001213900-26-090091.md) |
| Current liabilities | $m | [5.5](/filings/0001213900-23-086893.md) | [5.9](/filings/0001213900-25-030345.md) | [6.6](/filings/0001213900-24-044765.md) | [3.4](/filings/0001213900-24-068994.md) | [4.2](/filings/0001213900-24-098474.md) | [3.4](/filings/0001213900-26-036609.md) | [4.1](/filings/0001213900-25-091180.md) | [3.6](/filings/0001213900-25-091181.md) | [6.9](/filings/0001213900-25-110877.md) | [8.8](/filings/0001213900-26-090091.md) | [17.7](/filings/0001213900-26-058993.md) | [15.7](/filings/0001213900-26-090091.md) |
| Total liabilities | $m | [5.6](/filings/0001213900-23-086893.md) | [6.0](/filings/0001213900-25-030345.md) | [6.6](/filings/0001213900-24-044765.md) | [4.0](/filings/0001213900-24-068994.md) | [4.8](/filings/0001213900-24-098474.md) | [4.0](/filings/0001213900-26-036609.md) | [4.5](/filings/0001213900-25-091180.md) | [4.0](/filings/0001213900-25-091181.md) | [7.3](/filings/0001213900-25-110877.md) | [9.1](/filings/0001213900-26-090091.md) | [28.5](/filings/0001213900-26-058993.md) | [26.1](/filings/0001213900-26-090091.md) |
| Shareholders' equity | $m | [4.9](/filings/0001213900-24-098474.md) | [3.4](/filings/0001213900-26-036609.md) | [(1.5)](/filings/0001213900-25-091181.md) | [16.8](/filings/0001213900-25-110877.md) | [10.3](/filings/0001213900-25-110877.md) | [7.4](/filings/0001213900-26-090091.md) | [3.2](/filings/0001213900-26-090091.md) | [1.6](/filings/0001213900-26-090091.md) | [(1.7)](/filings/0001213900-25-110877.md) | [(3.5)](/filings/0001213900-26-090091.md) | [576](/filings/0001213900-26-090091.md) | [573](/filings/0001213900-26-090091.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(6,964) d](/filings/0001213900-24-098474.md) | [(5,249) d](/filings/0001213900-25-030345.md) | [(4,131)](/filings/0001213900-25-091180.md) | [(8,172) d](/filings/0001213900-25-091181.md) | [(5,675) d](/filings/0001213900-25-110877.md) | [(4,555) d](/filings/0001213900-26-036609.md) | [(4,303)](/filings/0001213900-26-058993.md) | [(3,096) d](/filings/0001213900-26-090091.md) | [(1,609) d](/filings/0001213900-25-110877.md) | [(2,260) d](/filings/0001213900-26-036609.md) | [(4,288)](/filings/0001213900-26-058993.md) | [(5,274) d](/filings/0001213900-26-090091.md) |
| Capital expenditure | $k | [12.0 d](/filings/0001213900-24-098474.md) | [13.0 d](/filings/0001213900-25-030345.md) | [6.0](/filings/0001213900-25-091180.md) | [0.0 d](/filings/0001213900-25-091181.md) | [(3.0) d](/filings/0001213900-25-110877.md) | [5.0 d](/filings/0001213900-26-036609.md) | not reported | not reported | not reported | not reported | [6,238](/filings/0001213900-26-058993.md) | [243 d](/filings/0001213900-26-090091.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.9](/filings/0001213900-23-086893.md) | [37.5](/filings/0001213900-24-044765.md) | [43.1](/filings/0001213900-24-068994.md) | [3.4](/filings/0001213900-24-098474.md) | [3.7](/filings/0001213900-25-091180.md) | [6.6](/filings/0001213900-25-091181.md) | [0.7](/filings/0001213900-25-110877.md) | [1.0](/filings/0001213900-26-058993.md) | [1.1](/filings/0001213900-26-090091.md) | [0.9](/filings/0001213900-25-110877.md) | [1.6](/filings/0001213900-26-058993.md) | [2.5](/filings/0001213900-26-090091.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 27,647,305 at 2026-08-11, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-090091.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.